Company intelligence / Profile preview

Sōlaria Biō

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Lead product SBD111 clinically validated to slow bone loss (pending peer review & publication); other pipeline assets addressing arthritis and aging are in preclinical and development stages[2][6].

Therapeutic areas: EndocrinologyImmunologyRheumatologyOther
Modalities: Live biotherapeutic product therapyMicrobial therapyDietary supplement (therapeutic food/medical food)
Industry: Biotech

Drug pipeline

2 assets

SBD121

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

ADM (Archer Daniels Midland) – technology licensing for use in novel food and beverage matrices[3]

Beyond the preview

Go deeper on Sōlaria Biō.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sōlaria Biō.

Explore the full profile